Journal of Practical Oncology ›› 2023, Vol. 37 ›› Issue (5): 416-421.doi: 10.11904/j.issn.1002-3070.2023.05.005

• Clinical Research • Previous Articles     Next Articles

A comparative study on the efficacy and adverse reactions of nituzumab and bevacizumab combined with synchronous radiotherapy and chemotherapy in the treatment of locally advanced cervical cancer

XUE Liangfang1, WANG Xinshu2, ZHANG Yunyan1, CHENG Haiyan1, JIN Hong1, WANG Yaoxian1, YANG Shanshan1, LI Qi1   

  1. 1. Department of Gynecologic Radiotherapy,Harbin Medical University Cancer Hospital,Harbin 150081,China;
    2. Department of Medicine,Nantong University
  • Received:2022-10-17 Revised:2023-02-14 Online:2023-10-28 Published:2024-03-18

PDF (PC)

12

Abstract: Objective The objective of this study was to compare the short-term efficacy and adverse reactions of nituzumab combined with synchronous radiotherapy and chemotherapy and bevacizumab combined with synchronous radiotherapy and chemotherapy in the treatment of locally advanced cervical cancer. Methods A total of 100 locally advanced cervical cancer patients with pathological type of squamous cell carcinoma were collected from 1 September 2020 to 31 December 2021.They were divided into a control group(synchronous radiotherapy and chemotherapy group),a nituzumab group(nituzumab combined synchronous radiotherapy group)and a bevacizumab group(bevacizumab combined synchronous radiotherapy and chemotherapy group).The total effective rate of short-term treatment,changes in tumor volume before and after treatment,serum squamous cell carcinoma antigen(SCC)levels before and after treatment,and adverse reactions after treatment were compared among patients of the three groups. Results The short-term total effective rates of the Nitro group,Bevar group and control group were 90.3%,87.2% and 60.0%,respectively.The total effective rates of the Nitro and Bevar groups were significantly higher than those of the control group,and the differences were statistically significant(P＜0.001).There was no statistically significant difference in the total effective rates of the Nitro and Bevar groups(P＞0.05);The degree of tumor volume reduction and SCC reduction in the Nituo group and Bevac group after treatment was higher than those in the control group(P＜0.05),and there was no statistically significant difference between the two groups(P＞0.05).The incidence of hypertension in the Bevar group was 33.4%,significantly higher than that in the control group(10.0%)and the Nitro group(12.9%)(P＜0.05).There was no statistically significant difference in the incidence of hypertension between the Nito group and the control group(P＞0.05);There was no statistically significant difference in the incidence of adverse reactions among the three groups except hypertension(P＞0.05). Conclusion Nituzumab combined with synchronous radiotherapy and chemotherapy,as well as bevacizumab combined with synchronous radiotherapy and chemotherapy,can improve the short-term efficacy of locally advanced cervical cancer,effectively reduce tumor volume and inhibit the expression of tumor markers,both of which are superior to synchronous radiotherapy and chemotherapy alone.Compared to bevacizumab,nituzumab has fewer adverse reactions.For patients with locally advanced cervical cancer,the combination of nituzumab and concurrent radiotherapy and chemotherapy is more reliable in terms of safety.

Key words: Cervical cancer, Locally advanced, Nituzumab, Bevacizumab, Synchronous radiotherapy and chemotherapy

CLC Number: